EN DE
STOCK COMPARISON

Genscript Biotech vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Genscript Biotech (1548) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Genscript Biotech trades at HK$31.46 versus a fair value of HK$15.52 (-51%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).
Genscript Biotech
1548.HK · HKD · Health Care
-51%
upside to fair value
overvalued
PriceHK$31.46
Fair ValueHK$15.52
Quality55/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$558
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Genscript BiotechVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
3.55×P/S (TTM)10.06×
0.86×P/B6.59×
10.2×EV/EBITDA23.8×
—PEG1.72×
−50.7%Fair value upside−50.0%
—Dividend yield0.1%
Profitability
17%Operating margin38%
—EBIT margin trend (5Y)0.86×
-13%Return on equity24%
3%Return on assets12%
Growth
43%Revenue growth (YoY)8%
15.3%Avg. growth/yr (3Y)10.6%
19.7%Avg. growth/yr (5Y)14.2%
—Value creation/yr+13.6%
Balance & size
14.7×Interest coverage (EBIT/interest)357.9×
—Debt / equity0.03×
$3BMarket cap$123B
mixedGrowth qualityhealthy

Even match: 5 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Genscript Biotechof which business quality 59 · market factors 73 Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
5
72
Quality GrowthAre margins and returns improving?
79
65
CashflowEarnings quality: real cash, not paper profit
89
79
Fin. StrengthBalance sheet, leverage, solvency risk
82
92
InvestmentDisciplined investing over empire-building
21
58
Low VolatilityCalm price path (market factor)
38
85
MomentumPrice trend over the last 3–12 months (market factor)
81
70
52W MomentumDistance to the 52-week high (market factor)
100
89
Net IssuanceBuybacks instead of dilution
71
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyGenscript BiotechPrice HK$31.46Vertex PharmaceuticalsPrice $558
DCF Models-90%below the priceHK$3.03-19%below the price$453
Earnings-Based-97%below the priceHK$1.06-8%close to the price$516
Dividend Discountn/a-99%below the price$7.07
Multiples-93%below the priceHK$2.07-50%below the price$278
Asset-Based-96%below the priceHK$1.21-91%below the price$49.27
Growth DCF-91%below the priceHK$2.92-38%below the price$348
Economic Profit-97%below the priceHK$1.06-54%below the price$254
Growth Earningsn/a+24%above the price$692
Minimum-97%below the priceHK$1.06-99%below the price$7.07
Maximum-90%below the priceHK$3.03+24%above the price$692
Median-95%below the priceHK$1.64-44%below the price$313
Geometric mean-95%below the priceHK$1.71-67%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Genscript Biotech: 13 of 13 models see the stock below the current price.

Vertex Pharmaceuticals: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Genscript Biotech
Bear HK$11.63Fair Value HK$15.52Bull HK$19.42
HK$31.46 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$558 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Genscript Biotech · Health Care

Quality score55 · above median
Fair value upside-51% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Genscript Biotech trades at HK$31.46 versus a fair value of HK$15.52 (-51%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Genscript Biotech · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Genscript Biotech

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Vertex Pharmaceuticals

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.